Home
overview

 

 
 

SMi proudly present their 3rd annual COPD: Novel Therapeutics and Management Strategies conference to be held in Central London on Wednesday 19th and Thursday 20th of October 2011. Bringing together high level industry representatives as well as highly respected academic and medical figures, this is your opportunity to enjoy presentations on the latest hot topics surrounding COPD and to network with key industry professionals.

This conference continues to promote increased awareness of COPD and explores ways to improve quality of life for patients, prevention of exacerbations and analyses the new treatment techniques developed over the previous twelve months.

The conference agenda covers every phase of COPD study. We begin with a clinical perspective taking into account new targets for COPD and lessons that can be learned in future development and desgin. The most controversial of these novel therapeutics, roflumilast, is explored from a pharmacological and clinical perspective. This is followed with looks at combination and inhaled therapeutics. 

The agenda focuses on discovery and devlopment from various interesting viewpoints, with pre and post clinical modelling and strategy addressed as well as Phase I & II studies.

 


 

Current Registered Attendess from the following companies include: Almirall, Argenta Discovery Ltd, Bayer Schering Pharma, Biomedical Systems Europe, Boehringer Ingelheim, Glaxosmithkline Biologicals, Grunenthal Gmb H, GSK, Hovione SA, Imperial College School of Medicine (N.H.L.I.), Johnson & Johnson, Kyorin Pharmaceutical Co Ltd, National Heart & Lung Institute, Nycomed GmbH, ProtAffin Biotechnologie AG, Revotar Biopharmaceuticals, Sandoz International Gmbh, Teva UK Limited, Vectura & Vitalograph Ltd

 

The conference will address:
  • Modeling and management of exacerbations of COPD - examine animal modelling and statistical outcomes
  • Uses, potential and controversy of new PDE4 compound inhibitors - explore the uses and potential of recently approved Roflumilast from the experiences of Nycomed themsleves and take a clinical perspective of its uses.
  • Unique complexities of COPD pathophysiology - compare and contrast COPD with Asthma to improve your understanding of what makes COPD unique and needing of particualr attention.
  • Combination and oxygen therapies - learn about triple therapies and novel therapies within the treatment of COPD
  • The clinical trials process and rapid proof of concept - improving your understanding of the clinical trials process to allow for quicker proof of concept, geting your ideas to market quicker and more safely
  • Improving case-finding and diagnosis - learn about patient phenotyping and how to diagnose COPD correctly and in good time
  • Analyse all phases of the discovery process, from pre-clinical modelling, phase 2 studies all the way through to modelling clincal outcomes.
 

Feedback from last year's guests included:

“Very good speakers”

“My aim in attending the conference was to get an update on current therapies and new target under investigation for asthma and COPD.  The conference met my needs very well so I’m pleased I attended.  Good networking opportunity as well.”

"Excellent conference, great speakers and venue" 

"I would recommend the conference"


 Industry professionals in positions such as:

 
  • Associate Clinician
  • Associate Director
  • Biomarker Specialist
  • Brand Manager
  • Business Development Director
  • CEO
  • Chief Executive Officer
  • Chief Medical Officer
  • Chief Scientific Officer
  • Clinical & Regulatory Strategy Manager
  • Clinical Pharmacologist
  • Clinical Trial Manager
  • Commercial Director
  • CSO
  • Director
  • Director of Medical Affairs
  • Head Global Licensing Respiratory
  • Head of Clinical Science
  • Head of Discovery
  • Head of Global Data Informatics - Global Preclinical R&D
  • Head of In-Vitro Biology
  • Head of Pharmacology
  • Head of Respiratory Pharmacology
  • Managing Director
  • Medical Affairs Director
  • Medical Director
  • Principal Scientist
  • Vice President
  • VP Chemistry
  • VP Inflammatory Disease Area
  • VP, Clinical Research Immunology
  • VP, Research

  

Attendees at previous SMi COPD events include: 3M Healthcare, 4SC, Accovion, Actelion, Actimis, Activaero, Aeropharm, AstraZeneca, Bayer, Bedfont Scientific, Biomedical Systems Europe, Biotie Therapies, Boehringer Ingelheim, CareFusion, Centocor, Chiesi, Deepbreeze, Galapagos, Genentech, GSK, Grunenthal, Laboratorios Almirall, MedImmune, Merck, Mpex, Munidpharma, Napp, Novartis, Nycomed, Pfizer,Revotar, Roche, Sanofi-Aventis, Schering Plough, Sepracor, Synairgen, Topigen, UCB, Vitalograph

 

 

 

Conference programme

8:30 Registration & Coffee

9:00 Chairman's Opening Remarks

Sebastian Johnston

Sebastian Johnston, Professor of Respiratory Medicine, Imperial College School of Medicine (N.H.L.I.)

9:10 Aetiology & pathogenesis of exacerbations of COPD

Sebastian Johnston

Sebastian Johnston, Professor of Respiratory Medicine, Imperial College School of Medicine (N.H.L.I.)

• Role of bacteria and viruses in COPD exacerbations
• Human and mouse models of COPD exacerbations
• Mechanisms of COPD exacerbations
• Identification of novel approaches to therapy

9:50 Reducing the burden of COPD by targeting skeletal muscle mass and function

Michael Steiner

Michael Steiner, Consultant Respiratory Physician, University Hospital Leicester

• Evidence to support the importance of skeletal muscle dysfunction in COPD
• The benefits of physical training
• The potential for the skeletal muscles to be a target for drug development in COPD.

10:30 Morning Coffee

11:00 COPD, a developing disease: clinical perspective and lessons from Asthma

Ewan Walters

Ewan Walters, Medical Director, Teva UK Ltd

• Pathogenesis
• COPD as a developing disease
• Development of COPD specific therapies
• Inherent difficulties with the disease
• A bright future?

11:40 Panel Discussion: Novel Therapeutics and unmet needs in COPD

Sebastian Johnston

Sebastian Johnston, Professor of Respiratory Medicine, Imperial College School of Medicine (N.H.L.I.)

12:40 Networking Lunch

13:50 Clinical testing and uses of ‘roflumilast’

Neil Barnes

Neil Barnes, Consultant Respiratory Physician, Barts & The London NHS Trust

• Deciding who should use roflumilast
• Correct dosages
• How long should it be used for
• What evidence of improvements to look for in patients using it
• When to stop administering roflumilast
 

14:30 Combination therapy for COPD

Mary Fitzgerald

Mary Fitzgerald, Executive VP, Respiratory, Pulmagen Therapeutics

• New ICS/LABA combinations: What and why
• Switching on Inhaled Corticosteroids: Novel anti-inflammatory combinations
• Combination bronchodilators: Optimising symptomatic benefit

15:10 Afternoon Tea

15:40 Inhaled models of Inflammation in Phase I/II clinical trials

Graham Clarke

Graham Clarke, Head of Respiratory Phase I, Quintlies Ltd.

• Integrated Phase I study designs
• Addressing mechanism of action
• Allergen, LPS and Ozone challenges
• Surrogate biomarkers – Nasal challenge

16:20 Anti-inflammatory therapies

Daniel Bock

Daniel Bock, Director Preclinical and Clinical R&D, Revotar Biopharmaceuticals

• Targeting inflammation in COPD: options and limitations
• Approved and emerging anti-inflammatory drugs for the treatment of COPD
• Translating anti-inflammatory potency into clinical benefit
 

17:00 Chairman’s Closing Remarks and Close of Day One

Sebastian Johnston

Sebastian Johnston, Professor of Respiratory Medicine, Imperial College School of Medicine (N.H.L.I.)

8:30 Registration & Coffee

9:00 Chairman's Opening Remarks

Maria Belvisi

Maria Belvisi, Head of Respiratory Pharmocology Group, Imperial College

9:10 Diagnosing and Phenotyping COPD Patients

Bill MacNee

Bill MacNee, Professor of Medicine, University Of Edinburgh Medical School

• COPD is a heterogeneous condition and although definition is based around the measurement of airflow limitation, the FEV1 does not describe the heterogeneity of the condition
• A number of proposed phenotypes of COPD have been suggested which may relevance for outcomes in COPD and targeted treatment
• COPD phenotypes and their clinical relevance will be described
• Future options for treatment targeted towards COPD phenotypes will be discussed

9:50 Targeting the immunological basis of COPD

Matthew Catley

Matthew Catley, Head of Disease Area Pharmacology, UCB

• The immunology of COPD
• Autoimmunity and COPD
• Targeting the immunopathology of COPD

10:30 Morning Coffee

11:00 Rodent models of COPD exacerbations

Liz Hardaker

Liz Hardaker, Investigator II, Novartis

• What are exacerbations and why target them?
• What aspects of exacerbations can be modelled in rodent models?
• How can we translate the findings back to man?

11:40 Pre-clinical models of COPD

Maria Belvisi

Maria Belvisi, Head of Respiratory Pharmocology Group, Imperial College

• Human and rodent tissue and cell based assays
• Pharmacodynamic models
• In vivo models of steroid resistant inflammation
• Functional endpoints

12:20 Networking Lunch

13:40 The Management of COPD exacerbations

Wisia Wedzicha

Wisia Wedzicha, Professor of Respiratory Medicine, University College London

  • Issues regarding acute exacerbations
  • Pharmacological & non-pharmacological management
  • Outcomes of exacerbations
  • Integration of services
  • Organisation of care

     

  • 14:20 Modelling clinical outcomes of COPD

    15:00 Panel Discussion: COPD clinical trials from start to finish

    Maria Belvisi

    Maria Belvisi, Head of Respiratory Pharmocology Group, Imperial College

    Graham Clarke

    Graham Clarke, Head of Respiratory Phase I, Quintlies Ltd.

    Wisia Wedzicha

    Wisia Wedzicha, Professor of Respiratory Medicine, University College London

    16:00 Afternoon Tea and Close of Day Two

    +

    Workshops

    Rapid Proof of Concept in COPD trials
    Workshop

    Rapid Proof of Concept in COPD trials

    The Grange Holborn Hotel
    18th October 2011
    London, United Kingdom

    The Grange Holborn Hotel

    50-60 Southampton Row
    London WC1B 4AR
    United Kingdom

    The Grange Holborn Hotel

    HOTEL BOOKING FORM

    Title

    SubTitle
    speaker image

    Content


    Title


    Description

    Download


    WHAT IS CPD?

    CPD stands for Continuing Professional Development’. It is essentially a philosophy, which maintains that in order to be effective, learning should be organised and structured. The most common definition is:

    ‘A commitment to structured skills and knowledge enhancement for Personal or Professional competence’

    CPD is a common requirement of individual membership with professional bodies and Institutes. Increasingly, employers also expect their staff to undertake regular CPD activities.

    Undertaken over a period of time, CPD ensures that educational qualifications do not become obsolete, and allows for best practice and professional standards to be upheld.

    CPD can be undertaken through a variety of learning activities including instructor led training courses, seminars and conferences, e:learning modules or structured reading.

    CPD AND PROFESSIONAL INSTITUTES

    There are approximately 470 institutes in the UK across all industry sectors, with a collective membership of circa 4 million professionals, and they all expect their members to undertake CPD.

    For some institutes undertaking CPD is mandatory e.g. accountancy and law, and linked to a licence to practice, for others it’s obligatory. By ensuring that their members undertake CPD, the professional bodies seek to ensure that professional standards, legislative awareness and ethical practices are maintained.

    CPD Schemes often run over the period of a year and the institutes generally provide online tools for their members to record and reflect on their CPD activities.

    TYPICAL CPD SCHEMES AND RECORDING OF CPD (CPD points and hours)

    Professional bodies and Institutes CPD schemes are either structured as ‘Input’ or ‘Output’ based.

    ‘Input’ based schemes list a precise number of CPD hours that individuals must achieve within a given time period. These schemes can also use different ‘currencies’ such as points, merits, units or credits, where an individual must accumulate the number required. These currencies are usually based on time i.e. 1 CPD point = 1 hour of learning.

    ‘Output’ based schemes are learner centred. They require individuals to set learning goals that align to professional competencies, or personal development objectives. These schemes also list different ways to achieve the learning goals e.g. training courses, seminars or e:learning, which enables an individual to complete their CPD through their preferred mode of learning.

    The majority of Input and Output based schemes actively encourage individuals to seek appropriate CPD activities independently.

    As a formal provider of CPD certified activities, SMI Group can provide an indication of the learning benefit gained and the typical completion. However, it is ultimately the responsibility of the delegate to evaluate their learning, and record it correctly in line with their professional body’s or employers requirements.

    GLOBAL CPD

    Increasingly, international and emerging markets are ‘professionalising’ their workforces and looking to the UK to benchmark educational standards. The undertaking of CPD is now increasingly expected of any individual employed within today’s global marketplace.

    CPD Certificates

    We can provide a certificate for all our accredited events. To request a CPD certificate for a conference , workshop, master classes you have attended please email events@smi-online.co.uk

    Event Title

    Headline

    Text
    Read More

    I would like to speak at an event

    I would like to attend an event

    I would like to sponsor/exhibit at an event

    SIGN UP OR LOGIN

    Sign up
    Forgotten Password?

    Contact SMi GROUP LTD

    UK Office
    Opening Hours: 9.00 - 17.30 (local time)
    SMi Group Ltd, 1 Westminster Bridge Road, London, SE1 7XW, United Kingdom
    Tel: +44 (0) 20 7827 6000 Fax: +44 (0) 20 7827 6001
    Website: http://www.smi-online.co.uk Email: events@smi-online.co.uk
    Registered in England No: 3779287 VAT No: GB 976 2951 71




    Forgotten Password

    Please enter the email address you registered with. We will email you a new password.